EMA/25525/2024

European Medicines Agency decision

P/0025/2024

of 31 January 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obicetrapib, (EMEA-003438-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0025/2024

of 31 January 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for obicetrapib, (EMEA-003438-PIP02-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the application submitted by NewAmsterdam Pharma BV on 24 April 2023 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 December 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for obicetrapib, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for obicetrapib, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for obicetrapib, tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to NewAmsterdam Pharma BV, Gooimeer 2-35, 1411 DC – Naarden, The Netherlands.

EMA/PDCO/426109/2023
Amsterdam, 15 December 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-003438-PIP02-23

Scope of the application

Active substance(s):

Obicetrapib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of elevated cholesterol

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

NewAmsterdam Pharma BV

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, NewAmsterdam Pharma BV submitted for agreement to the European Medicines Agency on 24 April 2023 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 22 May 2023.

Supplementary information was provided by the applicant on 8 September 2023.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of elevated cholesterol

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of elevated cholesterol

2.1.1. Indication(s) targeted by the PIP

Treatment of heterozygous familial hypercholesterolaemia (HeFH) and treatment of homozygous familial hypercholesterolaemia (HoFH)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Tablet

2.1.4. Measures

Area	**Description**
Quality-related studies	Not applicable.
Non-clinical studies	Not applicable.
Clinical studies	**Study 1** Double-blind, randomised, placebo-controlled trial to evaluate pharmacokinetics and pharmacodynamics of obicetrapib in children from 6 years to less than 18 years of age with heterozygous familial hypercholesterolaemia (HeFH). **Study 2** Double-blind, randomised, placebo-controlled trial to evaluate safety and efficacy of obicetrapib in children from 6 years to less than 18

	years of age with heterozygous familial hypercholesterolaemia (HeFH). **Study 3** Clinical trial to be performed with obicetrapib in children from 6 years to less than 18 years of age with homozygous familial hypercholesterolemia (HoFH). The key elements, including study design, controls to be included in the opinion must be based on cardiovascular safety and sufficient reduction in LDL-C must be agreed with the PDCO prior to the start of this study.
Modelling and simulation studies	**Study 4** Dose finding modelling and simulation study to select the dose for PIP Study 1 in children from 6 years to less than 18 years of age.
Other studies	Not applicable.
Extrapolation plan	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By November 2033
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.